Fluarix Quadrivalent regulatory update

GlaxoSmithKline submitted an sBLA to FDA for Fluarix Quadrivalent influenza vaccine for use in children ages ≥6 months. The intramuscular vaccine is approved in patients ages ≥3 to prevent disease cau...